Biosimilars approved for marketing Europe vs U.S. 2022 by year since approval
A higher number of approvals was shown in the U.S. as by the end of the seventh year, the U.S. had 33 biosimilars approved for marketing whereas Europe had 11 biosimilars approved. This statistic shows the cumulative number of biosimilars approved for marketing in Europe and the U.S., as of October 2022, by year since the first biosimilar was approved.
